Autoimmune hemolytic anemia, warm type
MONDO:0019532Warm autoimmune hemolytic anemia is the most common form of autoimmune hemolytic anemia defined by the presence of warm autoantibodies against red blood cells (autoantibodies that are active at temperatures between 37-40B0C).
Also known as: Warm Autoimmune Hemolytic Anemia, wAHA, wAIHA, warm AIHA, warm antibody AIHA, warm antibody autoimmune hemolytic anaemia, warm antibody autoimmune hemolytic anemia, warm antibody hemolytic anaemia
100 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Experimental immune therapy for stubborn anemia shows early promise but trial stalls
Disease control TerminatedThis early-phase trial tested whether low doses of interleukin-2 (IL-2), a protein that helps regulate the immune system, could help people with warm autoimmune hemolytic anemia (wAHAI) whose disease did not improve with standard steroid treatment. The study planned to give four …
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental drug tested for stubborn blood disorder – but trial cut short
Disease control TerminatedThis early-phase study tested the drug Linperlisib in just 4 adults with autoimmune hemolytic anemia (AIHA) whose disease did not improve after at least two prior treatments. The goal was to see if the drug could help control the disease by targeting a key immune pathway. However…
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can extra care after transplant help older patients live better?
Disease control TerminatedThis study tested two extra care programs—supportive palliative care and clinical management of other health issues—for older or frail patients who had a donor stem cell transplant. The goal was to see if these programs could improve quality of life and survival compared to stand…
Phase: PHASE2, PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Promising drug for rare blood disorder trial halted early
Disease control TerminatedThis phase 3 study tested the drug parsaclisib in people with primary warm autoimmune hemolytic anemia, a condition where the immune system destroys red blood cells. The trial aimed to see if parsaclisib could improve hemoglobin levels and reduce fatigue compared to a placebo. Ho…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Biopsy tolerance study ends early – what we know
Knowledge-focused TerminatedThis study aimed to understand how well patients tolerate biopsies for autoimmune diseases and whether they feel properly informed. It planned to enroll 505 people but was terminated early. The results may help improve patient experience with these common procedures.
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC